Octimet Oncology

Octimet Oncology is a private, clinical-stage biotech developing targeted kinase inhibitors for oncology, with a primary focus on the MET pathway. Its lead asset, OMO-1, is a highly selective oral MET inhibitor that has completed Phase 1 studies, while OMO-2 is a pre-clinical dual MET/RAS pathway inhibitor. The company has de-risked its development path through regional partnerships with Shanghai Allist for Greater China and DeuterOncology for the Rest of the World, positioning it to advance its pipeline with external funding and expertise. Octimet operates as a virtual or lean organization, leveraging partnerships to progress its innovative biomarker-based clinical strategies.

Integrated development of highly selective kinase inhibitors coupled with innovative patient selection and pharmacodynamic biomarker strategies.

OMO-1 competes in a market with approved MET inhibitors (capmatinib, tepotinib) and other candidates, requiring differentiation on selectivity, safety, or efficacy. OMO-2 enters the highly competitive and scientifically complex field of RAS pathway inhibition, competing against major pharmaceutical companies and well-funded biotechs with approved and pipeline assets.